Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05662-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Lucía Pérez-Lamas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Doctor José Molina Orosa, Lanzarote, Spain. Hauptthemen laut MEDLINE: Nitriles, Aniline Compounds, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML. A total of 36 patients were planned to be enrolled, but the study had to be prematurely terminated due to safety concerns. Nine patients were included in the study, and only 8 went on to receive the combination with atezolizumab. There were a total of 44 adverse events (AEs) during the study period. The most frequent were gastrointestinal (50%), mostly mild (86% grade 1-2). The most serious AEs were hepatic. There were 17 hepatic AEs in 5 patients. Of the hepatic AEs 5 were during the bosutinib monotherapy phase and 12 during the combination phase (AST increase x4, ALT increase x4, blood bilirubin increase x1, alkaline phosphatase elevation x2, GGT increase x2), most of them grade 3-4. There were 2 patients who presented a dose-limiting toxicity; a grade 3 elevation of transaminases, that led to premature termination of the study. The combination of atezolizumab with bosutinib presents hepatotoxicity as a dose-limiting effect and therefore we do not recommend to explore this combination in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Doctor José Molina Orosa, Lanzarote, Spain.
- Hospital Universitario La Paz, Madrid, Spain.
- Hospital Universitario Doce de Octubre, Madrid, Spain.
- Hospital Virgen de la Salud, Toledo, Spain.
- Hospital Universitario Central de Asturias, Oviedo, Spain.
- Hospital Universitario de Salamanca, Salamanca, Spain.
Zitieren
APA
Pérez-Lamas, L., de Paz Arias, R., Díaz, R. M. A., Montero, L. F. C., Payer, Á. R., Sierra, M., Marín, F. F., López, R. P., Cirici, B. X., Steegmann, J. L., Gómez Casares, M. T., Martínez-López, J., & García-Gutiérrez, V. (2024). Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05662-7
Vancouver
Pérez-Lamas L, de Paz Arias R, Díaz RMA, Montero LFC, Payer ÁR, Sierra M, et al. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05662-7
BibTeX
@article{PrezLamas2024,
author = {Pérez-Lamas, Lucía and de Paz Arias, Raquel and Díaz, Rosa Mª Ayala and Montero, Luis Felipe Casado and Payer, Ángel Ramírez and Sierra, Magdalena and Marín, Francisca Ferrer and López, Raúl Pérez and Cirici, Blanca Xicoy and Steegmann, Juan Luis and Gómez Casares, María Teresa and Martínez-López, Joaquín and García-Gutiérrez, Valentín},
title = {Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05662-7}
}
EUVIMED